Trial Profile
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms ADRIATIC
- Sponsors AstraZeneca; AstraZeneca AB
- 05 Apr 2024 According to an AstraZeneca media release, data from this trial will be presented at a forthcoming medical meeting and shared with global regulatory authorities. The second experimental arm testing the efficacy of IMJUDO (tremelimumab-actl) added to IMFINZI as a secondary endpoint remains blinded and will continue to the next planned analysis.
- 05 Apr 2024 Positive results from this trial presented in an AstraZeneca media release.
- 08 Mar 2023 Planned End Date changed from 23 Apr 2025 to 5 Sep 2024.